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Recent development in genome editing technologies has enabled site-directed
deprivation of a nucleotide sequence in the chromosome in mammalian cells.
Human immunodeficiency (HIV) infection causes integration of proviral DNA into the
chromosome, which potentially leads to re-emergence of the virus, but conventional
treatment cannot delete the proviral DNA sequence from the cells infected with HIV. In
the present study, the transcription activator-like effector nucleases (TALENs) specific for
the HIV p17 gene were constructed, and their activities to destroy the target sequence
were evaluated. SSA assay showed a high activity of a pair of p17-specific TALENs.
A human T lymphoid cell line, Jurkat, was infected with a lentivirus vector followed
by transfection with the TALEN–HIV by electroporation. The target sequence was
destructed in approximately 10–95% of the p17 polymerase chain reaction clones, and
the efficiencies depended on the Jurkat–HIV clones. Because p17 plays essential roles
for assembly and budding of HIV, and this gene has relatively low nucleotide sequence
diversity, genome editing procedures targeting p17 may provide a therapeutic benefit
for HIV infection.
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INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) causes latent infection in CD4+ T cells and
macrophages, in which HIV-1 provirus DNA is integrated into the chromosomes. The viral genome
is stably maintained in the cells and segregated into their progenies. Anti-HIV medicines such as
protease inhibitors and reverse transcriptase inhibitors drastically improved prognosis of HIV-1-
infected patients, by interfering with viral amplification (Pierson et al., 2000; Datta et al., 2016).
However, perfect cure of HIV infection has not been achieved, because provirus DNA cannot be
eliminated from the chromosomes of the infected cells by the present therapies.
Recent genome editing technologies including the zinc finger nuclease, transcription activator-
like effector nucleases (TALEN), and clustered regularly interspaced short palindromic repeat
(CRISPR)/Cas9 have made it possible to efficiently induce specific alteration or truncation
of target nucleotide sequence in the genomic DNA of mammalian cells (Jinwei et al., 2015;
Maeder and Gersbach, 2016; Mei et al., 2016). Such technologies may realize novel therapeutic
procedures against various genetic diseases by replacing and modifying the genes responsible for
the pathogenesis (Jang et al., 2016). Among them, TALEN is an artificial fusion enzyme composed
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of the nuclease domain and the DNA binding domain derived
from the TALEs of the Xanthomonas. Any nucleotide sequence
can be targeted by selecting the modules of the DNA-binding
domains.
If provirus DNA is destroyed using these technologies, such
procedures may provide a novel anti-HIV therapy that may not
only eliminate the potential risk of HIV reactivation and AIDS
onset but also relieve patients of potential adverse events and
economic burden due to lifelong medication. The transactivation
response element (TAR) sequence may be a suitable target (Ebina
et al., 2015; Strong et al., 2015), while another appropriate target
may be a coding sequence for an essential viral structural protein,
because truncation of only a small number of nucleotides in the
coding sequence may result in deletion of critical amino acid
residue(s) or frameshift mutation.
In this context, we constructed TALENs that target the HIV
Gag p17 gene, and examined if the p17 coding sequence in
the chromosome of HIV-infected cells can be destroyed by
transducing the recombinant TALEN vector.
MATERIALS AND METHODS
TALEN Vectors
Two pairs of TALENs, i.e., HIV TALEN 1 (HIV TALEN 1 L and
R) and HIV TALEN 2 (HIV TALEN 2 L and R) (Figure 1A)
were designed to recognize p17 gene sequence (Figure 1B), based
on the TAL Effector Nuclotide Targeter software.1 The TALEN
vectors were constructed using the Golden Gate reaction as
described previously.
Single-Strand Annealing (SSA) Assay
Single-strand annealing assay was performed as described
with slight modification (Sakuma et al., 2013). Two pairs of
oligonucleotides, HIV p17 TALEN No.1 SSA S and AS, and HIV
p17 TALEN No. 2 SSA S and AS (Figure 2A), were annealed to
form double strand oligonucleotides, which were subsequently
inserted into pGL4-SSA reporter plasmid that had been digested
by BsaI endonuclease. The resultant plasmids were named pGL4-
SSA-HIV_1 and 2. 293TN cells were seeded into 96-well plates
at a density of 6 × 104/well. On the next day, cells were co-
transfected with 20 ng of TALEN plasmid, 10 ng of pGL4-SSA,
and 2 ng of pRL-CMV vector as an internal control by means
of X-treme GENE 9 DNA Transfection Reagent (Roche). As a
positive control, other aliquot of the cells were co-transfected
with HPRT1 TALEN L1, HPRT1 TALEN R1, and pGL4-SSA-
HPRT1 (Sakuma et al., 2013). Twenty-four hours later, dual
luciferase assay was performed using Dual-Glo luciferase assay
system (Promega) and GENios (TECAN Inc.) device.
1https://tale-nt.cac.cornell.edu/
FIGURE 1 | Structure and target sequences of Human immunodeficiency (HIV) transcription activator-like effector nucleases (TALENs). (A) The amino
acid sequences of the repeat-variable di-residues (RVDs) of the indicated TALENs are shown with one-letter symbols. (B) The p17 gene sequence are shown.
Underlined letters (125–140 and 157–173) represent target sites of HIV 1 and 2 TALENs, respectively, while italic letters represent forward and reverse polymerase
chain reaction (PCR) primers (95–115, and 301–323, respectively) used for amplification of the p17 gene sequence from chromosomal DNA of Jurkat–HIV cells.
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FIGURE 2 | Efficient destruction of p17 sequence by the HIV-1 TALEN. (A) Sequences of the oligomers used in the SSA assay. (B) Each target sequence was
inserted into pGL4-SSA reporter plasmid. These reporter plasmids (+) or empty pGL4-SSA (−) was co-transfected with the indicated TALEN expression vector and
pRL-CMV reference plasmid into the 293TN cells. Twenty-four hours later, dual-Glo luciferase assay was performed to evaluate relative destruction of the target
sequence. Luc/R-Luc ratios are shown. In the presence of HPRT1–TALEN, the HPRT target sequence was efficiently destroyed, resulting in high rate of R-Luc
activity relative to Luc. HIV–TALEN1 destroyed its target sequence at an intermediate level, whereas HIV–TALEN2 showed very low destruction activity.
Lentivirus Vector
pGreen-puro vectors were purchaced from SBI. 293TN packaging
cells (3 × 106) were plated on geratin-coated 100 mm dishes
and cultured overnight. They were co-transfected with pGreen-
puro, pVSV-G, pPACKH1-REV, and pPACKH1-GAG using the
X-treme Gene 9 transfection reagent (Roche Applied Science,
Penzberg, Germany) diluted in Opti-MEM. Twenty-four hours
later, the culture supernatant was replaced by antibiotic-
free culture medium. After culturing for another 24 h, the
supernatant was collected and filtered through a 0.45 µm pore-
size filter.
Cells, Infection, and Transfection
Jurkat, a human T cell leukemia cell line, was cultured in the
RPMI1640 medium supplemented with 100 U/ml penicillin,
100 µg/ml streptomycin, and 10% FBS (Mazda et al., 1997). They
were seeded onto culture dishes at a density of 1 × 106 cells/mL.
On the next day, cells were transduced with the lentiviral vector
in the presence of 4 µg/mL polybrene (day 0). On day 1, cells
were reseeded onto 96 well plates at 0.3 cells/well. After culturing
with 1 µg/mL puromycin, three drug-resistant cell colonies were
randomly chosen and named Jurkat–HIV P1–P3. The colonies
were picked up and further cultured in puromycin-free medium.
TALEN expression vectors were then transfected into the cells by
electroporation (0.25 µg each of HIV TALEN 1 L and R vectors
for 105 cells).
PCR and DNA Sequencing
Four days after the transfection, DNA was extracted from
the cells. Polymerase chain reaction (PCR) was performed to
amplify the p17 gene sequence using the primers shown in
the Figure 1B. The resultant PCR fragments were inserted
into a TA cloning vector, MD20, which were subsequently
transformed into competent Escherichia coli. After seeding onto
ampicillin-containing agar plates, twenty colonies were picked
up. The sequence of each PCR clone was determined by standard
procedure using the SP6 and M13 primers.
RESULTS
The HIV TALENs 1 and 2 were prepared to target HIV gag p17
gene (Figure 1) and the activities of the TALENs were assessed
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by the SSA assay. The results are shown in Figure 2B. The HIV
TALENs 1 and 2 exhibited approximately 43 and 15% of activities
compared with that of the positive control TALEN that were
specific for hypoxanthine–guanine phosphoribosyl transferase
(HPRT) sequence (Sakuma et al., 2013). Based on the results, we
decided to use the HIV TALEN 1 that digests the HIV gag p17
gene sequence more efficiently than the HIV TALEN 2 in the
following experiments.
The T lymphoma cell line, Jurkat, was infected with a
lentivirus vector. After selection with puromycin, the resultant
clones were expected to possess the lentivirus sequence integrated
in their chromosomes. Thus, the lentivirus-infected Jurkat cells
were regarded as a model of the T cells latently infected with HIV.
Three clones (namely, Jurkat–HIV clone P1–P3) were transfected
with the HIV TALEN 1, and nucleotide sequences of the target
regions in PCR-amplified clones were determined.
The results are shown in Tables 1–3. In the Jurkat–HIV
clone P1, 19 out of 20 PCR clones showed truncation of
the p17 sequence (Table 1). The truncated sites spanned 7–
22 nucleotides. Therefore, the HIV TALEN 1 cleaved the HIV
sequence that had been integrated in the chromosome of Jurkat–
HIV clone P1 at quite high efficiency. In contrast, nucleotide
deletion was seen in only two out of twenty PCR clones derived
from the Jurkat–HIV clone P2 (Table 2). Seven nucleotides
were lacking in the p17 gene sequence in the two PCR clones.
Meanwhile, a half of PCR clones (10 out of 20) derived from
the Jurkat–HIV clone P3 possessed truncated p17 gene sequence
(Table 3).
TABLE 1 | Specific truncation of chromosomal DNA at p17 gene in
Jurkat–HIV clone P1.
Control agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
1 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
2 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
3 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
4 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
5 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
6 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
7 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
8 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
9 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
10 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
11 agaacgatt---------------------------gaaacatcagaaggctgt
12 agaacgatt---------------------------gaaacatcagaaggctgt
13 agaacgatt---------------------------gaaacatcagaaggctgt
14 agaacgatt---------------------------gaaacatcagaaggctgt
15 agaacgatt---------------------------gaaacatcagaaggctgt
16 agaacgatt----- ----------------------gaaacatcagaaggctgt
17 agaacgattcgcagtt-----------------agaaacatcagaaggctgt
18 agaacgattcgcagtt-----------------agaaacatcagaaggctgt
19 agaacgattcgcagtt-----------------agaaacatcagaaggctgt
20 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
Nucleotide sequences of 20 clones (No. 1–20) derived from PCR-amplified
fragments of p17 gene region in the chromosomal DNA of Jurkat–HIV clone P1
are shown. Control at the top represents wild type p17 sequence.
TABLE 2 | Specific truncation of chromosomal DNA at p17 gene in
Jurkat–HIV clone P2.
Control agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
1 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
2 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
3 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
4 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
5 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
6 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
7 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
8 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
9 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
10 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
11 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
12 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
13 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
14 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
15 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
16 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
17 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
18 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
19 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
20 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
Nucleotide sequences of 20 clones (No. 1–20) derived from PCR-amplified
fragments of p17 gene region in the chromosomal DNA of Jurkat–HIV clone P2
are shown. Control at the top represents wild type p17 sequence.
TABLE 3 | Specific truncation of chromosomal DNA at p17 gene in
Jurkat–HIV clone P3.
Control agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
1 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
2 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
3 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
4 agaacgattcgca--------ctggcctgttagaaacatcagaaggctgt
5 agaacgatt---------------------------gaaacatcagaaggctgt
6 agaacgatt---------------------------gaaacatcagaaggctgt
7 agaacgatt---------------------------gaaacatcagaaggctgt
8 agaacgatt---------------------------gaaacatcagaaggctgt
9 agaacgattcgcagtt-----------------agaaacatcagaaggctgt
10 agaacgattcgcagtt-----------------agaaacatcagaaggctgt
11 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
12 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
13 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
14 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
15 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
16 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
17 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
18 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
19 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
20 agaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgt
Nucleotide sequences of 20 clones (No. 1–20) derived from PCR-amplified
fragments of p17 gene region in the chromosomal DNA of Jurkat–HIV clone P3
are shown. Control at the top represents wild type p17 sequence.
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DISCUSSION
In the present study, the HIV TALEN 1 that we constructed
may highly efficiently edit the p17 sequence as suggested by
the SSA assay, although the reason why the other TALEN was
less efficient remains unknown. The TALEN induced cleavage
and truncation of the target sequence in the Jurkat–HIV cells,
leading to destruction of the coding sequence of the p17 gene.
In HIV-infected cells, the HIV-1 matrix protein p17 is excised
by proteolysis from the N-terminus of the Gag polyprotein, and
bring the Gag to the host cell membrane via its N-terminal
myristoyl group (Freed, 1998). Because the p17 is essential for
the assembly and budding of HIV virion, deletion of this gene
from the chromosome may bring remarkable therapeutic benefits
(Ellenrieder et al., 2004). The p17 gene has less sequence variation
among virus subtypes compared with the env genes (Brown and
Monaghan, 1988; Markham et al., 1995). Thus, the p17 gene
may be suitable as the target of the gene editing therapeutic
strategy.
We tested three Jurkat–HIV clones that we established by
limiting dilution after the infection with the lentivirus vector.
Interestingly, the three clones underwent p17 truncation at
different rates ranging from 10 to 95%. The variation among
the clones may be due to different integration sites of the
provirus sequence in the chromosomes, and/or difference in the
copy number of the integrated provirus per cell. Alternatively,
efficiency of electro-transfection of the TALEN vector may
differ among the Jurkat–HIV cell clones, resulting in different
proportion of the cells that sufficiently expressed TALEN
among the cell population. In the present study, the TALEN
vector was transfected into the cells once by electroporation. If
the electroporation is repetitively performed, the efficiency of
transfection may be elevated, resulting in a higher rate of p17 gene
truncation. Some delivery procedure other than electroporation
may also be used to transfer the TALEN vector into the cells to
increase the efficiency of the genome edition. A lentivirus vector
may be quite suitable for the delivery of a TALEN vector into T
cells in patients in whom HIV is latently infected.
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